Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
12.19
+0.10 (0.83%)
At close: Nov 4, 2024, 4:00 PM
12.71
+0.52 (4.27%)
After-hours: Nov 4, 2024, 7:59 PM EST

Company Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.

The company discovers, designs, and develop its initial programs candidates consists of VMT-α-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.

The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022.

Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Perspective Therapeutics, Inc.
Perspective Therapeutics logo
Country United States
Founded 1983
Industry Medical Devices
Sector Healthcare
Employees 119
CEO Johan Spoor

Contact Details

Address:
2401 Elliott Avenue, Suite 320
Seattle, Washington 98121
United States
Phone 206 676 0900
Website perspectivetherapeutics.com

Stock Details

Ticker Symbol CATX
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000728387
ISIN Number US46489V1044
Employer ID 41-1458152
SIC Code 3841

Key Executives

Name Position
Johan M. Spoor Chief Executive Officer and Director
Jonathan R. Hunt Chief Financial Officer and Principal Financial and Accounting Officer
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer
Shane Cobb Executive Vice President of Operations
Dr. Michael K. Schultz Ph.D. Chief Science Officer
Annie J. Cheng Vice President of Investor Relations
Andrew Bright Executive Vice President of Brachytherapy
Amos Hedt BA, PGradDip Chief Business Strategy Officer
Dr. Frances L. Johnson M.D. Chief Innovation Officer
David Hauser Ph.D. Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 11, 2024 8-K Current Report
Sep 20, 2024 8-K Current Report
Sep 12, 2024 144 Filing
Sep 5, 2024 8-K Current Report
Aug 30, 2024 8-K Current Report
Aug 19, 2024 8-K Current Report
Aug 14, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 13, 2024 8-K Current Report
Aug 13, 2024 424B5 Filing